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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of oral cryotherapy for preventing oral mucositis in patients with cancer who are receiving treatment.
B A C K G R O U N D
Description of the condition
Treating cancer with chemotherapy, radiotherapy of the head
and neck, or targeted therapy can cause toxic oral side effects
(Al-Dasooqi 2013; Scully 2006; Sonis 2004). Perhaps the most
widely researched of these side effects is oral mucositis (Al-Dasooqi
2013), which affects at least 75% of high risk patients (those re-
ceiving head and neck radiotherapy or high-dose chemotherapy)
(Scully 2006). Oral mucositis may be under-reported in lower risk
groups for various reasons: their tendency to be outpatients with
less observation; less reporting of moderate mucositis; or patients
and clinicians wishing to avoid any disruption to optimal cancer
treatment (Scully 2006).
Simply put, oral mucositis affects the oral mucosa (the mucous
membrane ofmoist tissue lining the oral cavity) and can lead to the
development of lesions (ulcers). However, the process that leads to
oral mucositis is complex andmultifactorial, with Sonis’ five phase
model being the currently accepted explanation for the sequence
of events underlying the condition (Sonis 2004; Sonis 2009):
1. Initiation: DNA damage caused by chemotherapy or
radiotherapy results in the loss of ability to proliferate in the
basal cells of the epithelium (the external layers of cells lining the
oral mucosa). This produces reactive oxygen species (ROS);
2. Primary damage response: Radiotherapy, chemotherapy,
ROS, and DNA strand breaks all contribute to the activation of
transcription factors such as nuclear factor kappa beta (NF-Kβ),
and sphingomyelinases. All this leads to the upregulation of pro-
inflammatory cytokines (e.g. tumour necrosis factor alpha -
TNF-α), nitric oxide, ceramide, and matrix metalloproteinases,
resulting in the thinning of the epithelium through tissue injury
and cell death, culminating with the destruction of the oral
mucosa;
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3. Signal amplification: Some of the molecules in the previous
phase can lead to the exacerbation and prolonging of tissue
injury through positive or negative feedback (e.g. TNF-α can
positively feedback on NF-Kβ thus inducing more pro-
inflammatory cytokine production);
4. Ulceration: Bacteria colonise ulcers and their cell wall
products infiltrate the submucosa (the connective tissues beneath
the oral mucosa), activating tissue macrophages (white blood
cells that respond to infection or damaged/dead cells), which
results in further production of pro-inflammatory cytokines,
inflammation, and pain;
5. Healing: Signalling from the extracellular matrix of the
submucosa results in epithelial proliferation and differentiation,
and thus a thickening of the epithelium. The local oral flora are
reinstated.
Understanding of the pathobiology leading to mucosal toxicity as
a result of targeted therapies (e.g. mammalian target of rapamycin
(mTOR) inhibitor-associated stomatitis - mIAS) is currently lim-
ited, but it is thought to differ from chemotherapy- and radio-
therapy-induced mucositis, and the clinical presentation of the
ulcers is more similar to aphthous stomatitis (Al-Dasooqi 2013;
Boers-Doets 2013; Peterson 2013a).
Chemotherapy-induced oral mucositis is regarded as an acute con-
dition, with ulceration normally occurring one week after treat-
ment, and resolving within three weeks of treatment (Sonis 2009).
Radiotherapy-induced oral mucositis is chronic in nature, with ul-
ceration normally occurring around two weeks into a seven-week
treatment cycle, and resolving three to four weeks after treatment
has ended (Sonis 2009).
Ulceration is the most significant phase as it leads to pain of vary-
ing severity, and difficulties with eating, swallowing, and talking
(Scully 2006). This in turn leads to the consumption of pain relief
medication, nutritional support (e.g. a feeding tube), treatment
of the oral mucositis, specialist oral hygiene care, increased medi-
cal appointments and use of staff and resources, and, in some in-
stances, hospitalisation (Jensen 2013; Miller 2001; Trotti 2003).
Thus the negative impact on the quality of life of cancer patients,
when they are already suffering, is severe (Elting 2008; Epstein
1999). Further problems can occur in immunosuppressed patients
if whole bacteria on the ulcer surface cross into the underlying
submucosa, potentially leading to bacteraemia and sepsis, which
require antibiotics and hospitalisation, and can cause death (Jensen
2013; Peterson 2013a; Scully 2006).
Therefore, oral mucositis can be a dose-limiting condition, dis-
rupting a patient’s optimal cancer treatment plan and consequen-
tially decreasing their chances of survival (Jensen 2013; Peterson
2013a; Sonis 2004). The additional costs associated with oral mu-
cositis are significant, with one study reporting a median incre-
mental cost of 18,515 US dollars per patient (Nonzee 2008).
Description of the intervention
Oral cryotherapy typically involves placing ice chips in the mouth
fiveminutes prior to chemotherapy and continuing for 30minutes
(Lalla 2008). The ice chips are typically rounded to avoid any
sharp edges or corners that may cause irritation to the patient,
and also so that they can be easily moved around in the mouth
(Karagözo lu 2005).
The advantages of using cryotherapy over other interventions are
its availability, cost-effectiveness, ease of administration, and safety
(in terms of lack of side-effects), and that it is well tolerated by
patients (Peterson 2013b).
How the intervention might work
The use of ice chips in the mouth cools the oral tissues and
causes the blood vessels to narrow (vasoconstriction), thus reduc-
ing bloodflow to the area and therefore also restricting the amounts
of the chemotherapy drugs delivered to the tissues (Lalla 2008;
Peterson 2013b; Scully 2006). Cryotherapy may only be effec-
tive in the prevention of oral mucositis in patients receiving che-
motherapy drugs that have a short half-life, such as bolus 5-fluo-
rouracil (5-FU), bolus edatrexate, and high-dose melphalan (Lalla
2008; Peterson 2013b; Scully 2006). Considering the mechanism
by which cryotherapy can prevent oral mucositis caused by che-
motherapy, it is unclear whether or not it could have any effect
on oral mucositis caused by radiotherapy (Lalla 2008). It is also
unclear whether or not cryotherapy could have any role in the
prevention of targeted therapy-induced stomatitis.
Why it is important to do this review
This review is the first of a series that will replace the previously
published Cochrane review covering all interventions for the pre-
vention of oral mucositis in patients with cancer receiving treat-
ment (Worthington 2011). The Mucositis Study Group (MSG)
of theMultinational Association of Supportive Care in Cancer/In-
ternational Society of Oral Oncology (MASCC/ISOO) is a group
that was set up in 1998 for the purpose of producing international
evidence-based clinical practice guidelines for managing mucosi-
tis (both oral and gastrointestinal), which they first published in
2004, with the latest update published in 2014 (Lalla 2014). In
order to facilitate the future updating of Cochrane reviews on this
topic, and also to make them more usable to clinicians, guideline
developers, and consumers, we have decided to divide the original
Cochrane review into the same intervention categories as those
used by MASCC/ISOO, which are as follows:
• Basic oral care/good clinical practice;
• Growth factors and cytokines;
• Anti-inflammatory agents;
• Antimicrobials, mucosal coating agents, anaesthetics, and
analgesics;
• Laser and other light therapy;
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• Cryotherapy;
• Natural and miscellaneous agents.
We believe that running in tandem with the MASCC/ISOO cat-
egories will enable the Cochrane reviews to more easily feed into
such guidelines. We will also be able to be more thorough and
rigorous in our assessment and summarising of the evidence in
each of the categories, which was not feasible in a single Cochrane
review approaching 150 included studies.
It is also important to do this review as it is consistently shown to
be the most used review produced by the Cochrane Oral Health
Group (in terms of full-text downloads). It was also ranked by an
expert panel of oral medicine specialists as being the most impor-
tant topic in the field of oral medicine in an international priori-
tisation exercise carried out by the Cochrane Oral Health Group
in 2014 (http://ohg.cochrane.org/priority-reviews).
O B J E C T I V E S
To assess the effects of oral cryotherapy for preventing oral mu-
cositis in patients with cancer who are receiving treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs) of parallel
design. It is possible to conduct cross-over studies in this area
as patients may receive several chemotherapy sessions, with any
mucositis completely healing in the periods between the sessions.
However, we will exclude cross-over studies as we cannot discount
any period effects, withmucositis risk increasing as patients receive
further cycles of treatment (Scully 2006; Sonis 2009).
Types of participants
We will include all patients with cancer who are receiving treat-
ment.
Types of interventions
We will include studies comparing oral cryotherapy for the pre-
vention of oral mucositis (inclusive of targeted therapy-induced
stomatitis) against placebo, no treatment, or any other treatment
to prevent oral mucositis.
We will exclude studies assessing different cancer treatments where
the primary outcome is survival/cure, with mucositis as a toxicity.
Types of outcome measures
We are in agreement with Williamson 2012 that, if clinical trials
and systematic reviews are to be utilised, the outcomes assessed
should be those considered important to patients, healthcare pro-
fessionals, and other key stakeholders. If outcomes and outcome
measures are inconsistent across studies, it will not be possible to
compare and summarise research, and there is potential for out-
come reporting bias, with the selective reporting of results based
on statistical significance and favourability (Clarke 2007; Dwan
2008; Williamson 2005). This can lead to exaggerated estimates
of effect in systematic reviews of interventions, leading to an in-
correct belief that an intervention is more beneficial that it truly is
(Clarke 2007). It is thought that the way to address this problem
is to develop disease- or condition-specific core outcome sets to be
used as a minimum when conducting and reporting clinical trials
(Clarke 2007; Williamson 2012).
Therefore we will use the core outcome set produced by Bellm
2002, which is registered on the COMET (Core Outcome Mea-
sures in Effectiveness Trials) Initiative’s website (www.comet-
initiative.org), and is the only core outcome set for oral mucositis
known to us.
Primary outcomes
Mucositis (at all levels of severity) using an appropriate, objective
scale. We will use mucositis measured on a 0 to 4 point scale
(none to severe) and dichotomise it as any mucositis (0 versus
1+), moderate to severe mucositis (0 to 1 versus 2+), and severe
mucositis (0 to 2 versus 3+).
Some studies measure mucositis using a composite scale. If it is
possible to extract the ’mucositis only’ data from the total score,
we will include the data in the analyses. If it is not possible, we
will record the composite data in an additional table.
Secondary outcomes
• Interruptions to cancer treatment;
• Oral pain;
• Quality of life;
• Normalcy of diet (including use of percutaneous
endoscopic gastrostomy (PEG) feeding tubes or total parenteral
nutrition (TPN));
• Adverse events;
• Number of days in hospital;
• Number of days of treatment with opioid analgesics;
• Number of days unable to take medicine orally.
Search methods for identification of studies
For the identification of studies included or considered for this
review, we will develop detailed search strategies for each database
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searched. These will be based on the search strategy we have devel-
oped for MEDLINE (OVID) (Appendix 1), which we will revise
appropriately for each database.
Electronic searches
We will search the following electronic databases:
• Cochrane Oral Health Group Trials Register (whole
database);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, current issue);
• MEDLINE via OVID (1946 to present) (Appendix 1);
• EMBASE via OVID (1980 to present);
• CANCERLIT via PubMed (1950 to present);
• CINAHL via EBSCO (1937 to present).
No restrictions will be placed on the language or date of publica-
tion when searching the electronic databases.
Searching other resources
We will search the following databases for ongoing trials:
• US National Institutes of Health Trials Register (http://
clinicaltrials.gov);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/
default.aspx).
We will only include handsearching done as part of the Cochrane
Worldwide Handsearching Programme and uploaded to CEN-
TRAL (see the Cochrane Masterlist (https://us.cochrane.org/
master-list) for details of journal issues searched to date).
Data collection and analysis
Selection of studies
Two review authors will independently screen the titles and ab-
stracts retrieved from the electronic searches. We will obtain full
text copies of all studies that appear to meet the inclusion criteria
of the review, or where there is insufficient information in the title
or abstract to make a clear judgement. Two review authors will
independently assess the full text copies for eligibility and resolve
any disagreements through discussion. We will consult a third re-
view author if we cannot resolve disagreements.
On assessing the full text article, we will discard any studies that
clearly do not meet the inclusion criteria. We will record all other
studies that do not meet the inclusion criteria, along with reasons
for exclusion, in the ’Characteristics of excluded studies’ table.
Data extraction and management
Two review authors will independently extract the data from each
included study using a specially designed data extraction form,
which we will first pilot on a small sample of studies. We will con-
tact study authors for clarification or missing data where necessary
and feasible. We will resolve any disagreements through discus-
sion, consulting a third review author to achieve consensus when
necessary.
We will record the following data for each included study in the
’Characteristics of included studies’ table.
• Trial design, location, number of centres, recruitment
period;
• Inclusion/exclusion criteria, age and gender of participants,
number randomised/analysed, any other potentially important
prognostic factors (e.g. cancer type, cancer treatment, etc.);
• Detailed description of the intervention and comparator,
including timing and duration. Information on compliance with
the cryotherapy regimen;
• Details of the outcomes reported, including method of
assessment and time(s) assessed;
• Details of sample size calculations, adverse effects, funding
sources, declarations/conflicts of interest.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each included study using the Cochrane domain-based, two-part
tool as described in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We will contact
study authors for clarification or missing information where nec-
essary and feasible. We will resolve any disagreements through
discussion, consulting a third review author to achieve consensus
when necessary.
We will complete a ’Risk of bias’ table for each included study. For
each domain of risk of bias, we will first describe what is reported
to have happened in the study. This will provide the rationale for
our judgement of whether that domain is at low, high, or unclear
risk of bias.
We will assess the following domains:
1. Sequence generation (selection bias);
2. Allocation concealment (selection bias);
3. Blinding of outcome assessment (detection bias);
4. Incomplete outcome data (attrition bias);
5. Selective outcome reporting (reporting bias);
6. Other bias.
We will not include the risk of bias domain ’blinding of partici-
pants and personnel (performance bias)’ as it will not be possible
to blind participants or personnel. This could lead to differences
in treatment for the patients (e.g. nurses could give people in the
placebo group extra care), which could have an effect on the out-
comes. Therefore we will consider all the studies to have a risk of
performance bias.
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Based on the remaining domains, we will categorise the overall risk
of bias of individual studies. Studies will be categorised as being at
low, high, or unclear risk of bias according to the following criteria:
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains are at low risk of bias;
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains are at high risk
of bias; or
• Unclear risk of bias (plausible bias that raises some doubt
about the results) if one or more domains are at unclear risk of
bias.
We will also present the ’Risk of bias’ summary graphically.
Measures of treatment effect
For continuous outcomes (e.g. oral pain on a visual analogue scale)
where studies use the same scale, we will use the mean values
and standard deviations (SDs) reported in the studies in order
to express the estimate of effect as mean difference (MD) with
95% confidence interval (CI). Where different scales are used, we
will express the treatment effect as standardised mean difference
(SMD) with 95% CI.
For dichotomous outcomes (e.g. mucositis of any severity/no mu-
cositis), we will express the estimate of effect as a risk ratio (RR)
with 95% CI.
Unit of analysis issues
The participant will be the unit of analysis.
Dealing with missing data
Where feasible, we will attempt to contact the author(s) of in-
cluded studies for clarification or missing data. We will use the
methods described in Section 7.7.3 of the Cochrane Handbook
for Systematic Reviews of Interventions to estimate missing SDs
(Higgins 2011). We will not use any other statistical methods or
perform any further imputation to account for missing data.
Assessment of heterogeneity
If a sufficient number of studies are included in any meta-anal-
yses, we will assess clinical heterogeneity by examining the char-
acteristics of the studies, the similarity between the types of par-
ticipants, the interventions, and the outcomes. We will also assess
heterogeneity statistically using a Chi² test, where a P value < 0.1
will indicate statistically significant heterogeneity. We will quan-
tify heterogeneity using the I² statistic. A guide to interpretation
of the I² statistic given in Section 9.5.2 of the Cochrane Handbook
for Systematic Reviews of Interventions is as follows (Higgins 2011):
• 0% to 40%: Might not be important;
• 30% to 60%: May represent moderate heterogeneity;
• 50% to 90%: May represent substantial heterogeneity;
• 75% to 100%: Considerable heterogeneity.
Assessment of reporting biases
If at least 10 studies are included in a meta-analysis, we will assess
publication bias according to the recommendations on testing for
funnel plot asymmetry (Egger 1997), as described in Section 10.4
of the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). If asymmetry is identified,wewill examine possible
causes.
Data synthesis
We will only carry out meta-analyses where there are studies of
similar comparisons reporting the same outcomes. We will com-
bine MDs (SMDs if studies use different scales) for continuous
data, and RRs for dichotomous data. Our general approach will
be to use a random-effects model. With this approach, the CIs for
the average intervention effect will be wider than those obtained
using a fixed-effect approach, leading to a more conservative in-
terpretation.
We will use an additional table to report the results from studies
not suitable for inclusion in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
Where there are sufficient studies, we intend to carry out the fol-
lowing subgroup analyses as mucositis incidence and severity may
vary according to these factors:
• Cancer type;
• Cancer treatment;
• Age group (children versus adults).
Sensitivity analysis
If a sufficient number of studies are included in any meta-analyses,
we will undertake sensitivity analyses to assess the robustness of
the results by excluding studies with unclear or high overall risk
of bias (whilst acknowledging that all studies are at high risk of
performance bias because blinding of participants and personnel
is not possible).
Inmeta-analyses that include several small studies and a single very
large study, we will undertake a sensitivity analysis comparing the
effect estimates from both random-effects and fixed-effect models.
If these are different we will report on both analyses as part of the
results section, and we will consider possible interpretation.
Presentation of main results
Wewill produce a ’Summary of findings’ table for each comparison
and for themain outcomes (listed below) usingGRADEmethods (
GRADE2004), andGRADEpro 2014 software.Wewill assess the
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quality of the body of evidence for each comparison and outcome
by considering the overall risk of bias of the included studies, the
directness of the evidence, the inconsistency of the results, the
precision of the estimates, and the risk of publication bias. We will
categorise the quality of each body of evidence as high, moderate,
low, or very low.
Main outcomes:
• Mucositis incidence;
• Interruptions to cancer treatment;
• Oral pain;
• Quality of life;
• Normalcy of diet;
• Adverse events;
• Number of days in hospital.
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A P P E N D I C E S
Appendix 1. MEDLINE (OVID) search strategy
1. exp NEOPLASMS/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. exp Antineoplastic agents/
6. Bone Marrow Transplantation/
7. neoplasm$.mp.
8. cancer$.mp.
9. (leukaemi$ or leukemi$).mp.
10. (tumour$ or tumor$).mp.
11. malignan$.mp.
12. neutropeni$.mp.
13. carcino$.mp.
14. adenocarcinoma$.mp.
15. lymphoma$.mp.
16. (radioth$ or radiat$ or irradiat$).mp.
17. (bone adj marrow adj5 transplant$).mp.
18. chemo$.mp.
19. or/1-18
20. exp STOMATITIS/
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21. Candidiasis, Oral/
22. stomatitis.mp.
23. mucositis.mp.
24. (oral adj6 mucos$).mp.
25. (mycosis or mycotic).mp.
26. mIAS.ti,ab.
27. or/20-26
28. Cryotherapy/
29. cryotherap$.mp.
30. (cold or freez$ or ice).mp.
31. or/28-30
32. 19 and 27 and 31
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